Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety

• Główni autorzy: N. Yu. Mironov (Autor), Yu. A. Yuricheva (Autor), V. V. Vlodzyanovskiy (Autor), S. F. Sokolov (Autor), Kh. M. Dzaurova (Autor), S. P. Golitsyn (Autor), Yu. V. Shubik (Autor), M. V. Berman (Autor), M. M. Medvedev (Autor), A. E. Rivin (Autor), D. S. Parkhomchuk (Autor), A. E. Barybin (Autor), D. А. Balandin (Autor), R. E. Batalov (Autor), D. V. Terekhov (Autor), I. V. Evstifeev (Autor), I. R. Kildeev (Autor), O. V. Pyataeva (Autor), S. A. Zenin (Autor)
• Format: Książka
• Wydane: Столичная издательская компания, 2021-11-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research center in cardiology) with data of other hospitals.Mat...